Exagen draws $5.3M for rheumatology Dx development

Exagen Diagnostics pulled in $5.3 million in new financing from a number of investors that it plans to use for both market growth and product development. Tullis Health Investors led the round, which also included Sun Mountain Capital, Cottonwood Technology Fund, Mesa Verde Venture Partners and Epic Ventures. Exagen already has three rheumatology-related diagnostic products and is developing a number of new ones to address rheumatology-related disorders. Release